Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice TargetHot
Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and lowers the price target from $59 to $53.
Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and lowers the price target from $59 to $53.